20 "Past Their Prime" Stocks to Dump From Your Portfolio in 2019

Posted on Wednesday, May 22nd, 2019 by MarketBeat Staff

Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2017. Even just 15 years ago, companies like Radio Shack, AOL, Yahoo and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.

As the years go by, some companies lose their luster and others rise to the top of the markets. We've already seen this in the last few decades with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega trend will be that will knock Apple, Google and Amazon off the top rankings of the S&P 500, but we do know that companies won't stay on the S&P 500 forever.

We've identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they are showing negative earnings growth for the next several years. If you own any of these stocks, consider selling them now before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.

#1 - Xencor (NASDAQ:XNCR)

Trailing Twelve Months EPS: ($1.31)
2019 EPS Estimate: ($0.08)
2020 EPS Estimate: ($1.84)

Stock Price: $33.12
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $41.8722 (26.4% Upside)

Xencor logoXencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

#2 - Sprint (NYSE:S)

Trailing Twelve Months EPS: $0.01
2019 EPS Estimate: ($0.07)
2020 EPS Estimate: ($0.09)

Stock Price: $6.66
P/E Ratio: 666.5
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $5.3925 (-19.0% Upside)

Sprint logoSprint Corporation, together with its subsidiaries, provides various wireless and wireline communications products and services to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the United States Virgin Islands. It operates in two segments, Wireless and Wireline. The Wireless segment offers wireless data communication services, including mobile productivity applications, such as Internet access, messaging, and email services; wireless photo and video offerings; location-based capabilities comprising asset and fleet management, dispatch services, and navigation tools; and mobile entertainment applications. It also provides wireless voice communications services that include local and long-distance wireless voice services, as well as voicemail, call waiting, three-way calling, caller identification, and call forwarding services. In addition, this segment offers voice and data services internationally through roaming arrangements; and customized wireless services to large companies and government agencies, as well as sells handsets, tablets, and hotspots. The Wireline segment provides wireline voice and data communications, which comprises domestic and international data communications using various protocols, including multiprotocol label switching technologies, Internet protocol (IP), managed network services, Voice over IP, session initiated protocol, and traditional voice services to other communications companies and targeted business subscribers. Sprint Corporation offers its services under the Sprint, Boost Mobile, Virgin Mobile, and Assurance Wireless brands. The company was founded in 1899 and is headquartered in Overland Park, Kansas. Sprint Corporation is a subsidiary of SoftBank Group Corp.

#3 - AU Optronics (NYSE:AUO)

Trailing Twelve Months EPS: $0.34
2019 EPS Estimate: ($0.16)
2020 EPS Estimate: ($0.22)

Stock Price: $2.90
P/E Ratio: 8.6
Dividend Yield: 12.20 %
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: N/A

AU Optronics logoAU Optronics Corp. researches, develops, produces, and sells thin film transistor liquid crystal displays and other flat panel displays. The company operates through two segments, Display and Solar. The Display segment designs, develops, manufactures, assembles, and markets flat panel displays for use in televisions (TVs), TV sets, and other related products; desktop monitors; mobile PCs, such as notebooks and tablets; mobile phones; and commercial and other applications, including displays for automobiles, industrial PCs, automated teller machines, point of sale terminals, pachinko machines, medical equipment, and others. This segment serves original equipment manufacturing service providers; and brand companies. The Solar segment manufactures and sells solar materials, including ingots, solar wafers, and solar modules, as well as provides technical engineering and maintenance services for solar system projects. This segment sells its ingot and solar wafer products primarily to solar cell manufacturers; and solar modules to installers, solar system integrators, property developers, and other value-added resellers. The company also engages in the renewable energy power generation; repairing and sale support of TFT-LCD modules, as well as sale support of solar-related products; injecting and stamping parts; manufacture and sale of molds, light guide plates, liquid crystal products, backlight modules, and related parts, as well as precision plastic and metal parts; IP related business; design, development and sales of software and hardware for health care industry; manufacture, assembly, and sale of automotive parts; manufacture and sale of motorized treadmills; and planning, design, and development of construction for environmental protection and related project management. It operates in the People's Republic of China, Taiwan, Japan, Singapore, and internationally. AU Optronics Corp. was founded in 1996 and is headquartered in Hsinchu, Taiwan.

#4 - Takeda Pharmaceutical (NYSE:TAK)

Trailing Twelve Months EPS: $1.07
2019 EPS Estimate: $0.34
2020 EPS Estimate: ($0.70)

Stock Price: $17.51
P/E Ratio: 16.3
Dividend Yield: 3.22 %
Consensus Rating: Buy
Ratings Breakdown: 1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A

Takeda Pharmaceutical logoTakeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has a collaboration agreement with Lupus Therapeutics Inc. to evaluate the investigational biologic TAK-079 as a potential new therapy for Lupus in a Phase 1 trial. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

#5 - Zscaler (NASDAQ:ZS)

Trailing Twelve Months EPS: ($0.31)
2019 EPS Estimate: ($0.27)
2020 EPS Estimate: ($0.34)

Stock Price: $76.30
Consensus Rating: Hold
Ratings Breakdown: 5 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $58.3333 (-23.5% Upside)

Zscaler logoZscaler, Inc. operates as a cloud security company worldwide. The company's flagship services include Zscaler Internet Access solution that connect users to externally managed applications, including software-as-a-service applications and Internet destinations; and Zscaler Private Access solution, which is designed to provide access to internally managed applications, either hosted internally in data centers, and private or public clouds. It serves customers in various industries, such as airlines and transportation, conglomerates, consumer goods and retail, financial services, healthcare, manufacturing, media and communications, public sector and education, technology, and telecommunications services. The company was formerly known as SafeChannel, Inc., and changed its name to Zscaler, Inc. in August 2008. Zscaler, Inc. was incorporated in 2007 and is headquartered in San Jose, California.

#6 - Alkermes (NASDAQ:ALKS)

Trailing Twelve Months EPS: ($0.07)
2019 EPS Estimate: ($0.37)
2020 EPS Estimate: ($0.53)

Stock Price: $25.02
Consensus Rating: Hold
Ratings Breakdown: 4 Buy Ratings, 5 Hold Ratings, 4 Sell Ratings.
Consensus Price Target: $40.3636 (61.3% Upside)

Alkermes logoAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

#7 - Liberty Braves Group Series C (NASDAQ:BATRK)

Trailing Twelve Months EPS: $0.10
2019 EPS Estimate: ($0.29)
2020 EPS Estimate: ($0.32)

Stock Price: $27.52
P/E Ratio: 275.8
Consensus Rating: N/A
Ratings Breakdown: 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A

Liberty Braves Group Series C logoThe Liberty Braves Group, through its subsidiary, Braves Holdings, LLC, owns the Atlanta Braves Major League Baseball Club, stadium, and mixed use development project. The company is based in Englewood, Colorado. The Liberty Braves Group is a subsidiary of Liberty Media Corporation.

#8 - Halozyme Therapeutics (NASDAQ:HALO)

Trailing Twelve Months EPS: ($0.56)
2019 EPS Estimate: ($0.42)
2020 EPS Estimate: ($0.47)

Stock Price: $15.49
Consensus Rating: Buy
Ratings Breakdown: 2 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $20.75 (34.0% Upside)

Halozyme Therapeutics logoHalozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; and ARGENX BVBA. The company was founded in 1998 and is headquartered in San Diego, California.

#9 - RingCentral (NYSE:RNG)

Trailing Twelve Months EPS: ($0.04)
2019 EPS Estimate: ($0.43)
2020 EPS Estimate: ($0.46)

Stock Price: $123.08
Consensus Rating: Buy
Ratings Breakdown: 14 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $120.4706 (-2.1% Upside)

RingCentral logoRingCentral, Inc. provides software-as-a-service solutions that enable businesses to communicate, collaborate, and connect primarily in North America. The company's products include RingCentral Office, provides communication and collaboration across various modes, including high-definition voice, video, SMS, messaging and collaboration, conferencing, online meetings, and fax through smartphones, tablets, PCs, and desk phones; RingCentral Professional, a cloud based virtual telephone service for professionals, as well as provides inbound call answering and management services, and includes inbound local, long-distance, and toll-free minutes; and RingCentral Fax that provides online fax capabilities that allow businesses to send and receive fax documents without a fax machine. Its products also comprise RingCentral Contact Center, a collaborative contact center solution that delivers omni-channel; and RingCentral Glip, a team messaging and collaboration solution that allows a range of teams to stay connected through various modes of communication through an integration with RingCentral Office. The company serves a range of industries, including financial services, healthcare, legal services, real estate, retail, technology, insurance, construction, hospitality, and state and local government, as well as others. It sells its products through a network of direct sales representatives, as well as sales agents and channel partners. The company was incorporated in 1999 and is headquartered in Belmont, California.

#10 - Akcea Therapeutics (NASDAQ:AKCA)

Trailing Twelve Months EPS: ($2.74)
2019 EPS Estimate: ($0.63)
2020 EPS Estimate: ($0.79)

Stock Price: $21.05
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $40.50 (92.4% Upside)

Akcea Therapeutics logoAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

#11 - Endocyte (NASDAQ:ECYT)

Trailing Twelve Months EPS: ($1.00)
2019 EPS Estimate: ($0.64)
2020 EPS Estimate: ($0.68)

Stock Price: $0.00
Consensus Rating: Buy
Ratings Breakdown: 2 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $21.00

Endocyte logoEndocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

#12 - Line (NYSE:LN)

2019 EPS Estimate: ($0.95)
2020 EPS Estimate: ($1.19)

Stock Price: $31.16
Consensus Rating: Hold
Ratings Breakdown: 5 Buy Ratings, 1 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $3,500.00 (11,132.3% Upside)

Line logoLINE Corporation provides a platform for mobile messaging and communication services, content distribution, and related services primarily in Japan, Taiwan, Thailand, Indonesia, and Hong Kong. The company offers LINE, a cross-platform messenger application that enable users to communicate through free instant messaging, stickers, and voice and video calls, as well as serves as a smart portal to its other applications and services. It also provides communication and content sales, and advertising services through the LINE platform; and advertising services through LINE advertising, and livedoor and NAVER Matome Web portals. The company was formerly known as NHN Japan Corporation and changed its name to LINE Corporation in April 2013. The company was founded in 2000 and is headquartered in Tokyo, Japan. LINE Corporation is a subsidiary of Naver Corporation.

#13 - Yext (NYSE:YEXT)

Trailing Twelve Months EPS: ($0.76)
2019 EPS Estimate: ($0.85)
2020 EPS Estimate: ($0.88)

Stock Price: $21.18
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $23.00 (8.6% Upside)

Yext logoYext, Inc. provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and synchronize it to its knowledge network in North America and internationally. The company offers Yext Knowledge Engine, a cloud-based global platform that enables businesses to control and manage their digital knowledge and make it available through its knowledge Network of approximately 150 third-party maps, apps, search engines, intelligent GPS systems, digital assistants, vertical directories, and social networks. Its Knowledge Engine is used by end consumers to discover new businesses, read reviews, and find answers to queries. Yext, Inc. serves luxury, retail, food, hospitality, and financial services industries. The company was founded in 2006 and is headquartered in New York, New York.

#14 - Studio City International (NYSE:MSC)

Trailing Twelve Months EPS: ($0.24)
2019 EPS Estimate: ($2.04)
2020 EPS Estimate: ($5.06)

Stock Price: $18.00
Consensus Rating: Sell
Ratings Breakdown: 0 Buy Ratings, 0 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $20.00 (11.1% Upside)

Studio City International logoStudio City International Holdings Ltd. is a gaming, retail and entertainment resort located in Cotai, Macau. It engages in the hospitality business and provision of gaming related services in Macau. The company was founded on August 2, 2000 and is headquartered in Hong Kong.

#15 - Tenable (NASDAQ:TENB)

Trailing Twelve Months EPS: ($1.36)
2019 EPS Estimate: ($1.02)
2020 EPS Estimate: ($1.12)

Stock Price: $29.77
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $38.8333 (30.4% Upside)

Tenable logoTenable Holdings, Inc. provides cybersecurity solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company enterprise software platform enables visibility into an organization's cyber exposure across the attack surface and deep insights that help organizations translate vulnerability data into business insights to understand and reduce their cybersecurity risk. It offers Tenable.io, a software as a service that manages and measures cyber exposure across a range of traditional information technology (IT) assets, such as networking infrastructure, desktops, and on-premises servers, as well as modern IT assets, such as cloud workloads, containers, Web applications, and Internet of Things and operational technology assets; and Tenable.sc, a solution to manage and measure cyber exposure across traditional information technology assets and can be run on-premises, in the cloud, or in a hybrid environment, as well as Industrial Security. The company was founded in 2002 and is headquartered in Columbia, Maryland.

#16 - Iovance Biotherapeutics (NASDAQ:IOVA)

Trailing Twelve Months EPS: ($1.27)
2019 EPS Estimate: ($1.19)
2020 EPS Estimate: ($1.36)

Stock Price: $16.58
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $26.2857 (58.5% Upside)

Iovance Biotherapeutics logoIovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

#17 - Loxo Oncology (NASDAQ:LOXO)

Trailing Twelve Months EPS: ($5.31)
2019 EPS Estimate: ($2.25)
2020 EPS Estimate: ($4.51)

Stock Price: $0.00
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $204.00

Loxo Oncology logoLoxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

#18 - Eidos Therapeutics (NASDAQ:EIDX)

Trailing Twelve Months EPS: ($1.86)
2019 EPS Estimate: ($1.51)
2020 EPS Estimate: ($1.92)

Stock Price: $27.20
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $30.2857 (11.3% Upside)

Eidos Therapeutics logoEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California.

#19 - 2U (NASDAQ:TWOU)

Trailing Twelve Months EPS: ($0.63)
2019 EPS Estimate: ($1.23)
2020 EPS Estimate: ($1.27)

Stock Price: $40.79
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $75.0909 (84.1% Upside)

2U logo2U, Inc. operates as an education technology company in the United States, Hong Kong, South Africa, and the United Kingdom. The company operates through two segments, Graduate Program Segment and Short Course Segment. It offers front-end technology and services, including online learning platform, student and faculty and immersion support, accessibility, admissions application advising, in-program student field placements, and faculty recruiting. The company provides back-end technology and services comprising graduate program launch and operations applications, university systems integration applications, content management system, admission application processing portal, customer relationship management, content development, student acquisition, and state authorization services. The company was formerly known as 2Tor Inc. and changed its name to 2U, Inc. in October 2012. 2U, Inc. was founded in 2008 and is headquartered in Lanham, Maryland.

#20 - Alector (NASDAQ:ALEC)

Trailing Twelve Months EPS: ($4.62)
2019 EPS Estimate: ($1.40)
2020 EPS Estimate: ($1.63)

Stock Price: $19.28
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $26.6667 (38.3% Upside)

Alector logoAlector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.





More on MarketBeat
12 Cheap Dividend Stocks to Buy Today12 Cheap Dividend Stocks to Buy Today
13 Stocks Institutional Investors Won13 Stocks Institutional Investors Won't Stop Buying
15 Technology Stocks that Analysts Love15 Technology Stocks that Analysts Love
12 Marijuana Stocks to Buy Now12 Marijuana Stocks to Buy Now
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Portfolio20 High-Yield Dividend Stocks that Could Ruin Your Retirement Portfolio
8 Stocks to Buy and Hold Despite Market Selloff8 Stocks to Buy and Hold Despite Market Selloff
Top Fifteen Highest-Rated Dividend CompaniesTop Fifteen Highest-Rated Dividend Companies





Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel